Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2023-04-03 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL
Foreign Filer Report
2023-04-03 English
Ultomiris recommended for NMOSD EU approval
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 0382V' and is dated '03 April 2023'. It contains a press release style announcement from AstraZeneca PLC regarding a positive opinion from the CHMP for Ultomiris. The text concludes with contact information for RNS and a disclaimer stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure is characteristic of a general regulatory announcement disseminated via the RNS system, which serves as a primary information provider for the London Stock Exchange. Since the content is a specific announcement (drug approval update) and not a full financial report (like 10-K or IR), nor a specific management/director change, the most appropriate general category for such a regulatory news service release that doesn't fit a more specific code (like DIV, ER, or MANG) is the general Regulatory Filings fallback, RNS.
2023-04-03 English
ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901
Foreign Filer Report
2023-03-30 English
AstraZeneca completes KYM agreement for CMG901
M&A Activity Classification · 1% confidence The document begins with 'RNS Number : 6711U' and is dated March 30, 2023. It details a specific corporate action: the completion of an exclusive global license agreement for a drug candidate (CMG901) and outlines the financial considerations ($63m upfront, up to $1.1bn milestones). The text concludes with standard boilerplate information from RNS (the news service of the London Stock Exchange) and an 'END' marker. This structure is characteristic of a regulatory news service announcement, which is a broad category for mandatory disclosures that don't fit specific SEC forms (like 10-K) or specific corporate actions (like DIV or M&A). Since it is a general regulatory announcement provided via RNS, the most appropriate classification is Regulatory Filings (RNS). It is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA).
2023-03-30 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2023-03-27 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is a formal notification disseminated via RNS (RNS Number: 2235U) on March 27, 2023. It details a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR), specifically the vesting of shares under a performance plan for the CEO, Pascal Soriot. This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it mentions RNS distribution and includes boilerplate regulatory text, the core content is the insider transaction report, not a general regulatory announcement (RNS) or a report publication announcement (RPA).
2023-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.